Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587791 · ClinicalTrials.gov registry record · Early Phase 1
Cannabidiol in Opioid Use Disorder and Chronic Pain
A Early Phase 1 study of Chronic Pain and Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04587791 is a Early Phase 1 study of Chronic Pain and Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 34 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04587791, a Early Phase 1 study of Chronic Pain and Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or buprenorphine. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at least 72 hours to limit carryover effects.
Conditions Studied
Interventions
- DRUG Saline
- DRUG 400 mg Cannabidiol
- DRUG 800 mg Cannabidiol
- DRUG 1200 mg Cannabidiol
Study Locations (1)
Connecticut
- Department of Veterans Affairs Hospital - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-12-08 |
| Est. Completion | 2026-08-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04587791
The ClinicalTrials.gov registry entry for NCT04587791 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 4 interventions - of which Saline is the first listed.
NCT04587791 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04587791 about?
NCT04587791 is a clinical study titled "Cannabidiol in Opioid Use Disorder and Chronic Pain". This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or bup...
What is the current status of trial NCT04587791?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 34 participants. The study started on 2021-12-08. Estimated completion is 2026-08-31.
What conditions does trial NCT04587791 study?
This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.
What interventions are being tested in trial NCT04587791?
The interventions under investigation include: Saline (DRUG), 400 mg Cannabidiol (DRUG), 800 mg Cannabidiol (DRUG), 1200 mg Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT04587791?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04587791 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
-
Immunologic Response to Negative Cognition in Persons With Chronic Pain
COMPLETED · Early Phase 1
-
Managing Chronic Pain in Veterans With Substance Use Disorders
COMPLETED · Early Phase 1
-
Non-Opioid Pramipexole and Pain
COMPLETED · Early Phase 1
-
Exploratory Evaluation of [11C]-NOP46
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.